Patient P-01574
Therapy response
Stable
Tolerance
Improving
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Stable
Discontinuation risk
51%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 31 NP-02 recommended — Dietary Support Protocol NP-02
- Day 32 Patient accepted — Started NP-02 in the companion
- Day 42 GI symptom burden −19% vs expected — Dietary Support Protocol NP-02
- Day 48 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 48 Tolerance state changed — Unstable → Improving
- Day 57 GI-04 recommended — GI Support Protocol GI-04
- Day 58 Patient accepted — Started GI-04 in the companion
- Day 66 GI symptom burden −32% vs expected — GI Support Protocol GI-04
- Day 72 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 48.
Primary contributors, last 14 days
- Inflammatory activity-11
- Toxicity-8
- GI instability-4
What helped?
- Dietary Support Protocol NP-02Day 31Result: symptom burden −19%
- GI Support Protocol GI-04Day 57Result: symptom burden −32%
LIFE OS recommendation
Monitoring Escalation ME-01
68%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 3 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Butyrate / short-chain fatty acid production ↓60
- MicrobiomeButyrate capacity 24/100
- MicrobiomeF. prausnitzii depleted
- Drug metabolism and exposure ↑40
- DNACYP2D6 poor metabolizer → higher exposure
- Inflammatory signalling ↓35
- MicrobiomeBacteroides fragilis expansion
- WearableHRV 29 ms, trending down
- Autonomic recovery ↑25
- WearableResting HR 74 bpm
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Poor metabolizerHigher exposure at standard dose
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 2.3 · butyrate capacity 24/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 31 ms
- Sleep
- 6.4 h
- Steps
- 6,976
- Resting HR
- 75 bpm
Daily log: GI score 36, nutritional resilience 53, adherence 53.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01483 | 28% | S14 | AD-05 | no change | 35 |
| P-01804 | 28% | S19 | AD-05 | improved | 61 |
| P-01377 | 27% | S11 | AD-05 | no change | 42 |
| P-01541 | 26% | S09 | AD-05 | no change | 43 |
| P-01679 | 26% | S12 | AD-05 | no change | 39 |
| P-01350 | 27% | S19 | BR-03 | no change | 34 |
| P-01689 | 26% | S13 | BR-03 | no change | 50 |
| P-01371 | 30% | S06 | CR-01 | improved | 63 |
| P-01430 | 30% | S05 | CR-01 | improved | 54 |
| P-01442 | 30% | S13 | CR-01 | improved | 61 |
| P-01696 | 30% | S20 | CR-01 | improved | 59 |
| P-01708 | 27% | S07 | CR-01 | improved | 59 |